Top

Published in:

17-11-2023 | Pleural Mesothelioma

Updates in Management of Malignant Pleural Mesothelioma

Authors: Alexius John, MBBS, FRACP, Hazel O’Sullivan, MB, BCh, BAO, Sanjay Popat, FRCP, PhD

Published in: Current Treatment Options in Oncology | Issue 12/2023

Opinion statement

Malignant pleural mesothelioma (MPM) is an aggressive asbestos-associated thoracic malignancy that is usually incurable. As demonstrated in the landmark MARS2 trial, surgical resection does not improve survival outcomes and its role in managing MPM is limited. Whilst platinum-pemetrexed chemotherapy in combination with bevacizumab was the standard first-line approach for unresectable disease, landmark phase 3 trials have now established the role of immune checkpoint inhibitors (CPIs) in the upfront management of unresectable disease: either nivolumab-ipilimumab or carboplatin-pemetrexed-pembrolizumab. Patient selection for optimal strategy remains an ongoing question. For relapsed disease novel genomic-based therapies targeting a range of aberrations including losses of the tumour suppressor genes BAP1, CDKN2A and NF2, are being evaluated. Nonetheless, the future of MPM therapeutics holds promise. Here we overview current treatment strategies in the management of MPM.

Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Malignant mesothelioma. Intern Med J. 2010;40(11):742–50. https://doi.org/10.1111/j.1445-5994.2010.02223.x.CrossRefPubMed

Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, Lin X, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS, NCD Global Health Research Group, Association of Pacific Rim Universities (APRU). Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792–802. https://doi.org/10.1016/j.jtho.2023.01.095.CrossRefPubMed

Royal College of Physicians. National mesothelioma audit report 2020 (Audit Period 2016–18). London: RCP; 2020.

Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, Lima VCC. Malignant pleural mesothelioma: an update. J Bras Pneumol. 2021;47(6): e20210129. https://doi.org/10.36416/1806-3756/e20210129.CrossRefPubMedPubMedCentral

Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475–88. https://doi.org/10.1038/nrc.2017.42.CrossRefPubMed

Pairman L, Beckert LEL, Dagger M, Maze MJ. Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study. Intern Med J. 2022;52(7):1154–9. https://doi.org/10.1111/imj.15725.CrossRefPubMedPubMedCentral

WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020.

Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, et al. Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743–50.CrossRefPubMedPubMedCentral

• Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^☆. Ann Oncol. 2022 Feb;33(2):129–142. https://doi.org/10.1016/j.annonc.2021.11.005. This reference is of outstanding importance as it is a recent guideline published by the European Society of Medical Oncology (ESMO) on the management of MPM.

10.

Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631–9. https://doi.org/10.1097/JTO.0b013e31826915f1.CrossRefPubMed

11.

Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O’Brien M, Thomas G, Senan S, O’Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J, MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72. https://doi.org/10.1016/S1470-2045(11)70149-8.CrossRefPubMedPubMedCentral

12.

Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–5. https://doi.org/10.1016/j.lungcan.2013.11.026.CrossRefPubMed

13.

Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99(2):472–80. https://doi.org/10.1016/j.athoracsur.2014.09.056.CrossRefPubMed

14.

Lim E, Darlison L, Edwards J, Elliott D, Fennell DA, Popat S, Rintoul RC, Waller D, Ali C, Bille A, Fuller L, Ionescu A, Keni M, Kirk A, Koh P, Lau K, Mansy T, Maskell NA, Milton R, Muthukumar D, Pope T, Roy A, Shah R, Shamash J, Tasigiannopoulos Z, Taylor P, Treece S, Ashton K, Harris R, Joyce K, Warnes B, Mills N, Stokes EA, Rogers C, MARS 2 Trialists. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020;10(9):e038892. https://doi.org/10.1136/bmjopen-2020-038892.CrossRefPubMedPubMedCentral

15.

Raskin J, Surmont V, Cornelissen R, Baas P, van Schil PEY, van Meerbeeck JP. A randomized phase 2 study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). Transl Lung Cancer Res. 2018;7(5):593–8. https://doi.org/10.21037/tlcr.2018.05.07.CrossRefPubMedPubMedCentral

16.

Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, Lovato E, Hughes V, Fox-Rushby JA, Sharples LD, MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118–27. https://doi.org/10.1016/S0140-6736(14)60418-9.CrossRefPubMed

17.

Matthews C, Freeman C, Sharples LD, Fox-Rushby J, Tod A, Maskell NA, Edwards JG, Coonar AS, Sivasothy P, Hughes V, Rahman NM, Waller DA, Rintoul RC. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase 3 trial. BMJ Open Respir Res. 2019;6(1): e000368. https://doi.org/10.1136/bmjresp-2018-000368.CrossRefPubMedPubMedCentral

18.

Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y, Musk AW. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91(1):9–10. https://doi.org/10.1038/sj.bjc.6601957.CrossRefPubMedPubMedCentral

19.

O’Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84(1):18–22. https://doi.org/10.1016/j.radonc.2007.05.022.CrossRefPubMed

20.

Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, Pepperell J, Howell T, Stewart SA, Penz E, Jordan N, Morley AJ, Zahan-Evans N, Smith S, Batchelor TJP, Marchbank A, Bishop L, Ionescu AA, Bayne M, Cooper S, Kerry A, Jenkins P, Toy E, Vigneswaran V, Gildersleve J, Ahmed M, McDonald F, Button M, Lewanski C, Comins C, Dakshinamoorthy M, Lee YCG, Rahman NM, Maskell NA. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094–104. https://doi.org/10.1016/S1470-2045(16)30095-X.CrossRefPubMedPubMedCentral

21.

Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, Edwards JG, Ezhil V, Gilligan D, Hatton M, Jegannathen A, Mansy T, Peake MD, Pemberton L, Rintoul RC, Snee M, Ryder WD, Taylor P, Faivre-Finn C. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase 3 randomized trial. J Clin Oncol. 2019;37(14):1200–8. https://doi.org/10.1200/JCO.18.01678.CrossRefPubMed

22.

Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343–73. https://doi.org/10.1200/JCO.2017.76.6394.CrossRefPubMed

23.

Macleod N, Price A, O’Rourke N, Fallon M, Laird B. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review. Lung Cancer. 2014;83(2):133–8. https://doi.org/10.1016/j.lungcan.2013.11.004.CrossRefPubMed

24.

MacLeod N, Chalmers A, O’Rourke N, Moore K, Sheridan J, McMahon L, Bray C, Stobo J, Price A, Fallon M, Laird BJ. Is radiotherapy useful for treating pain in mesothelioma?: A Phase 2 Trial. J Thorac Oncol. 2015;10(6):944–50. https://doi.org/10.1097/JTO.0000000000000499.CrossRefPubMed

25.

Ashton M, O'Rourke N, Macleod N, Laird B, Stobo J, Kelly C, Alexander L, Franks K, Moore K, Currie S, Valentine R, Chalmers AJ. SYSTEMS-2: a randomised phase 2 study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Lung Cancer. 2023 Apr; 168 (Supplement 1, S22-S23). Abstract only. https://doi.org/10.1016/S0169-5002(23)00477-4

26.

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651–8. https://doi.org/10.1016/S1470-2045(15)00208-9.CrossRefPubMed

27.

Cho BCJ, Donahoe L, Bradbury PA, Leighl N, Keshavjee S, Hope A, Pal P, Cabanero M, Czarnecka K, McRae K, Tsao MS, de Perrot M. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021;22(2):190–7. https://doi.org/10.1016/S1470-2045(20)30606-9.CrossRefPubMed

28.

Chen Z, Dominello MM, Joiner MC, Burmeister JW. Proton versus photon radiation therapy: a clinical review. Front Oncol. 2023;29(13):1133909. https://doi.org/10.3389/fonc.2023.1133909.CrossRef

29.

Tsao AS, Pass HI, Rimner A, Mansfield AS. New era for malignant pleural mesothelioma: updates on therapeutic options. J Clin Oncol. 2022;40(6):681–92. https://doi.org/10.1200/JCO.21.01567.CrossRefPubMedPubMedCentral

30.

Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM. A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res. 2023;29(3):548–59. https://doi.org/10.1158/1078-0432.CCR-22-2566.CrossRefPubMed

31.

Cui W, Popat S. Pleural mesothelioma (PM) - the status of systemic therapy. Cancer Treat Rev. 2021;100: 102265. https://doi.org/10.1016/j.ctrv.2021.102265.CrossRefPubMed

32.

• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase 3 study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. doi: https://doi.org/10.1200/JCO.2003.11.136. Corrected and republished in: J Clin Oncol. 2023 Apr 20;41(12):2125–2133. This reference is of importance as it is a phase 3 study establishing the role of doublet chemotherapy in standard of care first line management of MPM.

33.

van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase 3 study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–9. https://doi.org/10.1200/JCO.20005.14.589.CrossRefPubMed

34.

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase 2 study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443–8. https://doi.org/10.1200/JCO.2005.04.3190.CrossRefPubMed

35.

Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase 2 study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370–3. https://doi.org/10.1093/annonc/mdm501.CrossRefPubMed

36.

Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase 2 study. Clin Lung Cancer. 2010;11(1):30–5. https://doi.org/10.3816/CLC.2010.n.005.CrossRefPubMed

37.

Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756–63. https://doi.org/10.1097/JTO.0b013e31817c73d6.CrossRefPubMed

38.

EMA/CHMP/260350/2021. Committee for Medicinal Products for Human Use (CHMP). 22 April 2021

39.

Dudek AZ, Wang X, Gu L, Duong S, Stinchcombe TE, Kratzke R, Borghaei H, Vokes EE, Kindler HL. Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901. Clin Lung Cancer. 2020;21(6):553-561.e1. https://doi.org/10.1016/j.cllc.2020.06.025.CrossRefPubMedPubMedCentral

40.

de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, van Walree N, van Heemst RC, Soud MY, Groen HJM, den Brekel AJS, Buikhuisen WA, Bootsma GP, Dammeijer F, van Tinteren H, Lalezari F, Aerts JG, Burgers JA, NVALT19 study group. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med. 2021;9(6):585–92. https://doi.org/10.1016/S2213-2600(20)30362-3.CrossRefPubMed

41.

Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, Rudd RM, Gaba A, Busacca S, Nixon L, Gardner G, Darlison L, Poile C, Richards C, Jordan PW, Griffiths G, Casbard A. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial. EClinicalMedicine. 2022;19(48): 101432. https://doi.org/10.1016/j.eclinm.2022.101432.CrossRef

42.

Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O’Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, López Castro R, García Campelo R, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, Stahel RA. A multicentre randomised phase 3 trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734–45. https://doi.org/10.1016/j.annonc.2020.09.009.CrossRefPubMed

43.

König J, Tolnay E, Wiethege T, Müller K. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration. 2000;67(1):36–40. https://doi.org/10.1159/000029460.CrossRefPubMed

44.

Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 2005;128(5):3382–7. https://doi.org/10.1378/chest.128.5.3382.CrossRefPubMed

45.

•• Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405–1414. https://doi.org/10.1016/S0140-6736(15)01238-6. Erratum in: Lancet. 2016 Apr 2;387(10026):e24. This reference is of outstanding importance as it is a large phase 3 registrational trial demonstrating the benefit of bevacizumab in addition to chemotherapy as a viable first line treatment strategy.

46.

Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S. LUME-Meso: design and rationale of the phase 3 part of a placebo-controlled study of nintedanib and pemetrexed/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2017;18(5):589–93. https://doi.org/10.1016/j.cllc.2017.03.010.CrossRefPubMed

47.

Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P. A randomized phase 2 study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol. 2016;11(5):758–68. https://doi.org/10.1016/j.jtho.2016.01.014.CrossRefPubMed

48.

Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase 2 trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naïve patients with unresectable malignant pleural mesothelioma (SWOG S0905). J Clin Oncol. 2019;37(28):2537–47. https://doi.org/10.1200/JCO.19.00269.CrossRefPubMedPubMedCentral

49.

Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22(10):1438–47. https://doi.org/10.1016/S1470-2045(21)00404-6.CrossRefPubMed

50.

• Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104–11. https://doi.org/10.1016/S1470-2045(13)70381-4. This reference is of importance as it was one of the early trials highlighting the role of CPI (initially using CTLA-4 inhibition) in the management of MPM.CrossRefPubMed

51.

Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301–9. https://doi.org/10.1016/S2213-2600(15)00092-2.CrossRefPubMed

52.

Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–73. https://doi.org/10.1016/S1470-2045(17)30446-1.CrossRefPubMed

53.

Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623–30. https://doi.org/10.1016/S1470-2045(17)30169-9.CrossRefPubMed

54.

Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G, CONFIRM trial investigators. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530–40. https://doi.org/10.1016/S1470-2045(21)00471-X.CrossRefPubMedPubMedCentral

55.

Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451–60. https://doi.org/10.1016/S2213-2600(18)30151-6.CrossRefPubMed

56.

Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260–70. https://doi.org/10.1016/S2213-2600(18)30420-X.CrossRefPubMed

57.

• Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G, French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239–53. https://doi.org/10.1016/S1470-2045(18)30765-4. Erratum. In: Lancet Oncol. 2019 Mar; 20(3):e132. This reference is of importance as it is a large phase 2 trial demonstrating the benefit of dual CTLA/PD1 inhibition in comparison with PD1 inhibition alone in pre-treated MPM.CrossRefPubMed

58.

•• Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86. https://doi.org/10.1016/S0140-6736(20)32714-8. Erratum. In: Lancet. 2021 Feb 20;397(10275):670. This reference is of outstanding importance as it is the first registrational phase III trial to established ipilimumab/nivolumab as a viable first line therapeutic regimen for MPM.CrossRefPubMed

59.

Chu S, Piccirillo MC, Greillier L, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Bradbury P, Morabito A, Letizia Cecere F, Delfanti S, Scherpereel A, Locatelli-Sanchez M, Zalcman G, Dawe, DE, Sederias J, Laurie SA, Lee CW, Tu W, Seymour L. IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients 9pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. Journal of Clinical Oncology. 2023;41(17_supp).LBA8505-LBA8505. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA8505

60.

Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153–9. https://doi.org/10.1038/nrc3459.CrossRefPubMedPubMedCentral

61.

Xu D, Yang H, Schmid RA, Peng RW. Therapeutic landscape of malignant pleural mesothelioma: collateral vulnerabilities and evolutionary dependencies in the spotlight. Front Oncol. 2020;23(10): 579464. https://doi.org/10.3389/fonc.2020.579464.CrossRef

62.

Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, Barbour H, Corbeil L, Hébert J, Drobetsky E, Masson JY, Di Noia JM, el Affar B. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 2014;111(1):285–90. https://doi.org/10.1073/pnas.1309085110.CrossRefPubMed

63.

Marchesi I, Bagella L. Targeting enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment. World J Clin Oncol. 2016;7(2):135–48. https://doi.org/10.5306/wjco.v7.i2.135.CrossRefPubMedPubMedCentral

64.

Betti M, Casalone E, Ferrante D, Aspesi A, Morleo G, Biasi A, Sculco M, Mancuso G, Guarrera S, Righi L, Grosso F, Libener R, Pavesi M, Mariani N, Casadio C, Boldorini R, Mirabelli D, Pasini B, Magnani C, Matullo G, Dianzani I. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 2017;1(405):38–45. https://doi.org/10.1016/j.canlet.2017.06.028.CrossRef

65.

Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, Takinishi Y, Yamamoto R, Minaai M, Hashimoto-Tamaoki T, Ohmuraya M, Goto K, Goparaju C, Sarin KY, Tanji M, Bononi A, Napolitano A, Gaudino G, Hesdorffer M, Yang H, Carbone M. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36(35):JCO2018790352. https://doi.org/10.1200/JCO.2018.79.0352.CrossRefPubMed

66.

Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81. https://doi.org/10.1093/carcin/bgu227.CrossRefPubMed

67.

Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019;116(18):9008–13. https://doi.org/10.1073/pnas.1821510116.CrossRefPubMedPubMedCentral

68.

Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A, MiST1 study group. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593–600. https://doi.org/10.1016/S2213-2600(20)30390-8.CrossRefPubMed

69.

Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M, Forster M, Cameron RB, Peikert T, Argon EK, Michaud NR, Szanto A, Yang J, Chen Y, Kansra V, Agarwal S, Fennell DA. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022;23(6):758–67. https://doi.org/10.1016/S1470-2045(22)00277-7.CrossRefPubMed

70.

Marshall K, Jackson S, Jones J, Holme J, Lyons J, Barrett E, Taylor P, Bishop P, Hodgson C, Green M, Telford N, Evison M. Homozygous deletion of CDKN2A in malignant mesothelioma: diagnostic utility, patient characteristics and survival in a UK mesothelioma centre. Lung Cancer. 2020;150:195–200. https://doi.org/10.1016/j.lungcan.2020.10.020.CrossRefPubMed

71.

Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51–6. https://doi.org/10.1002/cncr.10923.CrossRefPubMed

72.

Paajanen J, Bueno R, De Rienzo A. The rocky road from preclinical findings to successful targeted therapy in pleural mesothelioma. Int J Mol Sci. 2022;23(21):13422. https://doi.org/10.3390/ijms232113422.CrossRefPubMedPubMedCentral

73.

Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, Nusrat N, Scotland M, Bhundia V, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Bajaj A, Richards C, Wells-Jordan P, Thomas A, MiST2 study group. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):374–81. https://doi.org/10.1016/S1470-2045(22)00062-6.CrossRefPubMed

74.

Chapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. Mod Pathol. 2022;35(10):1383–97. https://doi.org/10.1038/s41379-022-01081-z.CrossRefPubMedPubMedCentral

75.

Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–16. https://doi.org/10.1038/ng.3520.CrossRefPubMed

76.

Sato T, Sekido Y. NF2/merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19(4):988. https://doi.org/10.3390/ijms19040988.CrossRefPubMedPubMedCentral

77.

Yap T, Kwiatkowski DJ, Desai J, Dagago-Jack I, Millward M, Kindler H, Tolcher AW, Frentzas S, Thurston A, Post L, Dorr FA. First-in-class, first-in-human phase 1 trial of VR3989, an inhibitor of Yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD0, in patients with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. https://vivacetherapeutics.com/wp-content/uploads/Vivace-Therapeutics-2023-AACR-Presentation.pdf. Accessed 01/08/2023.

78.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res. 2006;12(23):7126–31. https://doi.org/10.1158/1078-0432.CCR-06-1101.CrossRefPubMed

79.

Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 2002;62(19):5443–50.PubMed

80.

Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67(1):309–17. https://doi.org/10.1158/0008-5472.CAN-06-1945.CrossRefPubMed

81.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol. 2017;3(1):58–66. https://doi.org/10.1001/jamaoncol.2016.3049.CrossRefPubMed

82.

Szlosarek PW, Creelan B, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield A, Tsao A, O’Byrne K, Nowak AK, Steele J, Sheaff M, Johnston A, Bomalaski J, Zauderer M, Fennell DA. Abstract CT007: Phase 2–3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma. Cancer Res. 2023;83(8_Supplement):CT007–CT007. https://doi.org/10.1158/1538-7445.AM2023-CT007.

83.

Krebs MG, Branson A, Barber S, Poile C, King A, Greystoke A, Moody S, Nolan L, Scotland M, Darlison L, Bajaj A, Morgan B, Brookes C, Wells-Jordan P, Richards CJ, Thomas AL, Fennell DA. Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy. Journal of clinical oncology. 2023;41(16_supp):8511–8511. https://doi.org/10.1200/JCO.2023.41.16_suppl.8511. Journal of Clinical Oncology 41, no.16_suppl (June 01, 2023) 8511-8511.CrossRef

84.

Fennell DA, King A, Branson A, Barber S, Greystoke A, Dulloo S, Poile C, Harber J, Scotland M, Darlison L, Bajaj A, Morgan B, Brookes C, Wells-Jordan P, Richards CJ, Thomas A. Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4- a phase IIa trial with cellular and molecular correlates of efficacy. Journal of clinical oncology. 2023;40(16_supp):8560–8560. https://doi.org/10.1200/JCO.2022.40.16_suppl.8560. Journal of Clinical Oncology40, no.16_suppl (June 01, 2022) 8560-8560.CrossRef

85.

Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol. 2010;5(2):275–9. https://doi.org/10.1097/JTO.0b013e3181c5e366.CrossRefPubMedPubMedCentral

86.

Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(4):447–56. https://doi.org/10.1016/S1470-2045(15)70056-2. Erratum in: Lancet Oncol. 2015 May;16(5):e199.CrossRefPubMed

87.

Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Clin Epigenetics. 2018;18(10):79. https://doi.org/10.1186/s13148-018-0517-9.CrossRef

88.

Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC. Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res. 2018;24(4):766–76. https://doi.org/10.1158/1078-0432.CCR-17-2522.CrossRefPubMed

Title: Updates in Management of Malignant Pleural Mesothelioma
Authors: Alexius John, MBBS, FRACP
Hazel O’Sullivan, MB, BCh, BAO
Sanjay Popat, FRCP, PhD
Publication date: 17-11-2023
Publisher: Springer US
Keywords: Pleural Mesothelioma
Cancer Immunotherapy
Cytostatic Therapy
Targeted Therapy
Radiotherapy
Surgery
Pleural Mesothelioma
Mesothelioma
Published in: Current Treatment Options in Oncology / Issue 12/2023
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-023-01148-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 12/2023

The Evolving Treatment Landscape of Medullary Thyroid Cancer

Cardiovascular AEs of tyrosine kinase inhibitors in CML

Extent of Resection and Outcomes of Patients with Primary Malignant Brain Tumors

Precision medicine in urothelial carcinoma

Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System

Treatment of non-small-cell lung cancer with atypical EGFR mutations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer